FDA clears Amneal’s generic TobraDexIQVIA data for the year ended May 2021 showed annual U.S. sales of TobraDex and its generics was $118 million. AAM report: Medicare plans lag in adopting new genericsThe Association for Accessible Medicines’ latest report found that Medicare Part D plans are slow to add new generics to their formularies and often place them on nongeneric pricing tiers. Sandoz launches generic Feraheme Sandoz’s ferumoxytol is the first generic high-dose intravenous iron to treat patients with iron deficiency anemia. Aurobindo obtains FDA OK for generic Lioresal Baclofen tablets have a market value of roughly $77 million for the 12 months ended May 2021, according to IQVIA. Xiromed releases generic Nebcin Nebcin and its generics had a market value of $16 million for the 12-month period ended April 2021, according to IQVIA. FDA tentatively approves Unichem’s generic Januvia Unichem's generic Januvia is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus. Hikma intros succinylcholine chloride injection Succinylcholine chloride injection had a market value of roughly $43 million in the 12 months ended May 2021, according to IQVIA. Study examines cost to Medicare of delayed Humira biosimilars The study compared the European Union system for biosimilar introduction to that of the United States and evaluated the savings that would have arisen from the presence of multiple biosimilars of Humira. Lupin launches generic Kerydin Lupin's generic Kerydin is an antifungal for the treatment of onychomycosis of toenails. Breckenridge debuts generic Ambien CR Ambien CR and its generics had a market value of $42 million during the 12 months ended May 2021, according to industry sales data. First Previous 120 121 122 123 124 Next Last
